Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 465.61% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Benchmark lifted their target price on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. TD Cowen restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Price Performance

Shares of NASDAQ:HUMA traded up $0.01 on Tuesday, hitting $4.42. 261,992 shares of the company’s stock were exchanged, compared to its average volume of 2,998,319. The business’s 50 day simple moving average is $4.55 and its two-hundred day simple moving average is $5.65. The stock has a market capitalization of $556.30 million, a price-to-earnings ratio of -3.36 and a beta of 1.32. Humacyte has a 12 month low of $2.69 and a 12 month high of $9.97.

Insider Transactions at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock worth $6,606,799 over the last 90 days. 11.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. State Street Corp increased its position in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares in the last quarter. Millennium Management LLC grew its position in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC raised its stake in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares during the period. Marshall Wace LLP lifted its stake in shares of Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after purchasing an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new position in shares of Humacyte during the 2nd quarter worth approximately $1,550,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.